 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Provista Launching Clinical Study of Breast Cancer Dx, Could Submit 510(k) This Year
January 25, 2013
Provista Launching Clinical Study of Breast Cancer Dx, Could Submit 510(k) This Year
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Florida Licenses Provista Dx for Clinical Lab Services
May 7, 2013 / GenomeWeb Daily News - MDx Firm Provista Diagnostics Brings in $6M in Series A Financing
April 16, 2013 / GenomeWeb Daily News - CPTAC, Seoul National University to Test Proteomic Workflows Including MRM-MS in Clinical Setting
February 8, 2013 / ProteoMonitor - CPTAC Organizers, Researchers Offer Update on Plans and Progress as Project Data Portal Goes Live
September 21, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor